Jason Luke, MD: The Role of LDH, Age, and Sites of Disease in Durability of Response
What role might Sarah's LDH, age, and sites of disease play in the durable response that she experienced?
CASE: Metastatic Melanoma
Sarah is a 50-year-old Caucasian postal worker who presented to her primary care physician with multiple, skin-colored nodules and palpable lymph nodes. .
- A workup, biopsy, and mutation test was conducted, which revealed BRAF V600E mutation-positive melanoma that had metastasized to the lymph nodes, subcutaneous tissue, and right adrenal gland.
- ECOG performance status is 0 and her LDH levels are normal.
The patient was started on the combination of dabrafenib and trametinib. She experienced a durable complete response and has remained on therapy for 36 months.
Recent Videos
Related Content
10-Year Data From CheckMate 067 Confirms Survival Advantage of Nivolumab in Advanced Melanoma
September 15th 2024Article
Nivolumab, alone or with ipilimumab, significantly improved 10-year overall and melanoma-specific survival vs ipilimumab alone in advanced melanoma, according to final phase 3 CheckMate 067 trial data.
Read More
